Black Rock Inc. Viracta Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 273,297 shares of VIRX stock, worth $40,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares

273,297

Previous 303,980 10.09%

Holding current value

$40,994

Previous $310,000 52.58%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.5 - $1.17 $15,341 - $35,899	-30,683 Reduced 10.09%	273,297 $147,000
Q1 2024 May 10, 2024	SELL	$0.48 - $1.13 $802 - $1,889	-1,672 Reduced 0.55%	303,980 $310,000
Q4 2023 Feb 13, 2024	SELL	$0.44 - $1.04 $367 - $869	-836 Reduced 0.27%	305,652 $174,000
Q3 2023 Nov 13, 2023	SELL	$1.03 - $1.58 $158,359 - $242,920	-153,747 Reduced 33.41%	306,488 $318,000
Q2 2023 Aug 11, 2023	BUY	$0.89 - $2.13 $11,066 - $26,484	12,434 Added 2.78%	460,235 $648,000
Q1 2023 May 12, 2023	SELL	$1.38 - $2.29 $378 - $627	-274 Reduced 0.06%	447,801 $712,000
Q4 2022 Feb 13, 2023	SELL	$1.26 - $4.38 $270,301 - $939,619	-214,525 Reduced 32.38%	448,075 $654,000
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $398,961 - $683,761	120,169 Added 22.15%	662,600 $2.83 Million
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $3.31 Million - $8.85 Million	-1,770,477 Reduced 76.55%	542,431 $2.1 Million
Q1 2022 May 12, 2022	SELL	$2.23 - $4.76 $124,902 - $266,607	-56,010 Reduced 2.36%	2,312,908 $11 Million
Q4 2021 Feb 10, 2022	BUY	$3.37 - $7.91 $956,641 - $2.25 Million	283,870 Added 13.61%	2,368,918 $8.65 Million
Q3 2021 Nov 09, 2021	BUY	$7.84 - $12.53 $187,195 - $299,178	23,877 Added 1.16%	2,085,048 $16.7 Million
Q2 2021 Aug 11, 2021	BUY	$7.55 - $12.95 $15.6 Million - $26.7 Million	2,061,171 New	2,061,171 $23.4 Million

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $5.63M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account